Zoektermen

Vereos Digital PET/CT

The world's first and only true digital PET/CT system

Bekijk soortgelijke producten

The Philips Vereos PET/CT scanner with Digital Photon Counting will redefine PET imaging and mark a new era in clinical performance. In a recent survey¹, 9 out of 10 referring physicians prefer Vereos Digital PET images over analog².

Neem contact op
Kenmerken
Digital Photon Counting

Digital Photon Counting

Unlike analog PET/CT scanners that use photomultipliers, or analog SiPMs to detect light, the Vereos PET/CT scanner uses proprietary Digital Photon Counting (DPC) technology. DPC technology converts light directly to a digital signal with zero analog noise.

Digital Photon Counting

Unlike analog PET/CT scanners that use photomultipliers, or analog SiPMs to detect light, the Vereos PET/CT scanner uses proprietary Digital Photon Counting (DPC) technology. DPC technology converts light directly to a digital signal with zero analog noise.

Digital Photon Counting

Unlike analog PET/CT scanners that use photomultipliers, or analog SiPMs to detect light, the Vereos PET/CT scanner uses proprietary Digital Photon Counting (DPC) technology. DPC technology converts light directly to a digital signal with zero analog noise.
1:1 coupling

1:1 coupling

Each crystal is connected to a single digital photon counting detector. This 1:1 coupling, combined with 325 ps Time-of-Flight (TOF) timing resolution and reduced pile-up effects, allows for a much higher count rate capability and improved spatial resolution compared to analog² systems.

1:1 coupling

Each crystal is connected to a single digital photon counting detector. This 1:1 coupling, combined with 325 ps Time-of-Flight (TOF) timing resolution and reduced pile-up effects, allows for a much higher count rate capability and improved spatial resolution compared to analog² systems.

1:1 coupling

Each crystal is connected to a single digital photon counting detector. This 1:1 coupling, combined with 325 ps Time-of-Flight (TOF) timing resolution and reduced pile-up effects, allows for a much higher count rate capability and improved spatial resolution compared to analog² systems.
Improved lesion detectability

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]
≈ 2x volumetric resolution³

≈ 2x volumetric resolution³

The system uses 1:1 coupling of crystals to digital detectors. This means spatial, timing, and energy resolution is improved throughout the entire field of view, for improved volumetric resolution.

≈ 2x volumetric resolution³

The system uses 1:1 coupling of crystals to digital detectors. This means spatial, timing, and energy resolution is improved throughout the entire field of view, for improved volumetric resolution.

≈ 2x volumetric resolution³

The system uses 1:1 coupling of crystals to digital detectors. This means spatial, timing, and energy resolution is improved throughout the entire field of view, for improved volumetric resolution.
Low PET dose

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]
Fast scans

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]
Ready for the future

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.
  • Digital Photon Counting
  • 1:1 coupling
  • Improved lesion detectability
  • ≈ 2x volumetric resolution³
Bekijk alle kenmerken
Digital Photon Counting

Digital Photon Counting

Unlike analog PET/CT scanners that use photomultipliers, or analog SiPMs to detect light, the Vereos PET/CT scanner uses proprietary Digital Photon Counting (DPC) technology. DPC technology converts light directly to a digital signal with zero analog noise.

Digital Photon Counting

Unlike analog PET/CT scanners that use photomultipliers, or analog SiPMs to detect light, the Vereos PET/CT scanner uses proprietary Digital Photon Counting (DPC) technology. DPC technology converts light directly to a digital signal with zero analog noise.

Digital Photon Counting

Unlike analog PET/CT scanners that use photomultipliers, or analog SiPMs to detect light, the Vereos PET/CT scanner uses proprietary Digital Photon Counting (DPC) technology. DPC technology converts light directly to a digital signal with zero analog noise.
1:1 coupling

1:1 coupling

Each crystal is connected to a single digital photon counting detector. This 1:1 coupling, combined with 325 ps Time-of-Flight (TOF) timing resolution and reduced pile-up effects, allows for a much higher count rate capability and improved spatial resolution compared to analog² systems.

1:1 coupling

Each crystal is connected to a single digital photon counting detector. This 1:1 coupling, combined with 325 ps Time-of-Flight (TOF) timing resolution and reduced pile-up effects, allows for a much higher count rate capability and improved spatial resolution compared to analog² systems.

1:1 coupling

Each crystal is connected to a single digital photon counting detector. This 1:1 coupling, combined with 325 ps Time-of-Flight (TOF) timing resolution and reduced pile-up effects, allows for a much higher count rate capability and improved spatial resolution compared to analog² systems.
Improved lesion detectability

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]
≈ 2x volumetric resolution³

≈ 2x volumetric resolution³

The system uses 1:1 coupling of crystals to digital detectors. This means spatial, timing, and energy resolution is improved throughout the entire field of view, for improved volumetric resolution.

≈ 2x volumetric resolution³

The system uses 1:1 coupling of crystals to digital detectors. This means spatial, timing, and energy resolution is improved throughout the entire field of view, for improved volumetric resolution.

≈ 2x volumetric resolution³

The system uses 1:1 coupling of crystals to digital detectors. This means spatial, timing, and energy resolution is improved throughout the entire field of view, for improved volumetric resolution.
Low PET dose

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]
Fast scans

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]
Ready for the future

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Documentatie

Brochure (1)

Brochure

Brochure (1)

Brochure

Bekijk alle documentatie

Brochure (1)

Brochure

Technische specificaties

Minimum Room Size
Minimum Room Size
Exam room
  • Length 731.5 cm
  • Width 472.4 cm
Control room
  • Length 193 cm
  • Width 472.4 cm
Scanner Characteristics
Scanner Characteristics
Gantry with table dimensions
  • Length: 484.9 cm
  • Width: 220.3 cm
  • Height: 206.5 cm
Weight
  • 4,211 kg
Key specifications
Key specifications
Detector design
  • Digital Photon Counting (DPC)
Number of PET detectors
  • 23,040
PET timing resolution
  • 325 ps FWHM
TOF localization accuracy
  • 4.9 cm
PET effective sensitivity per cm
  • 1,342 cps/MBq/cm
PET quantitative accuracy
  • +/- 5%
Minimum Room Size
Minimum Room Size
Exam room
  • Length 731.5 cm
  • Width 472.4 cm
Control room
  • Length 193 cm
  • Width 472.4 cm
Scanner Characteristics
Scanner Characteristics
Gantry with table dimensions
  • Length: 484.9 cm
  • Width: 220.3 cm
  • Height: 206.5 cm
Weight
  • 4,211 kg
Bekijk alle specificaties
Minimum Room Size
Minimum Room Size
Exam room
  • Length 731.5 cm
  • Width 472.4 cm
Control room
  • Length 193 cm
  • Width 472.4 cm
Scanner Characteristics
Scanner Characteristics
Gantry with table dimensions
  • Length: 484.9 cm
  • Width: 220.3 cm
  • Height: 206.5 cm
Weight
  • 4,211 kg
Key specifications
Key specifications
Detector design
  • Digital Photon Counting (DPC)
Number of PET detectors
  • 23,040
PET timing resolution
  • 325 ps FWHM
TOF localization accuracy
  • 4.9 cm
PET effective sensitivity per cm
  • 1,342 cps/MBq/cm
PET quantitative accuracy
  • +/- 5%
  • ¹In a recent survey of referring oncologists
  • ²GEMINI TF PET/CT
  • ³Compared to GEMINI TF PET/CT
  • ⁴Improved image quality is defined by improvements in spatial resolution and/or noise reduction as measured in phantom studies.
  • ⁵Buchan, K. (Philips Healthcare), Dharaiya E. (Philips Healthcare), Ardley N. (Monash Health, Australia) “Impact of workflow tools in reducing total exam and user interaction time - 4 phase liver computed tomography exams.”

Door op de link te klikken, verlaat u de officiële website van Royal Philips ("Philips"). Alle links naar websites van derden die op deze site kunnen verschijnen, zijn alleen bedoeld voor uw gemak en vertegenwoordigen op geen enkele manier enige aansluiting bij of goedkeuring van de informatie die op die gelinkte websites wordt verstrekt. Philips geeft geen verklaringen of garanties van welke aard dan ook met betrekking tot websites van derden of de daarin opgenomen informatie.

Ik begrijp het

You are about to visit a Philips global content page

Continue

Door op de link te klikken, verlaat u de officiële website van Royal Philips ("Philips"). Alle links naar websites van derden die op deze site kunnen verschijnen, zijn alleen bedoeld voor uw gemak en vertegenwoordigen op geen enkele manier enige aansluiting bij of goedkeuring van de informatie die op die gelinkte websites wordt verstrekt. Philips geeft geen verklaringen of garanties van welke aard dan ook met betrekking tot websites van derden of de daarin opgenomen informatie.

Ik begrijp het

You are about to visit a Philips global content page

Continue
© Koninklijke Philips N.V., 2004 - 2024. Alle rechten voorbehouden.

U kunt onze website het beste bekijken met de nieuwste versie van Microsoft Edge, Google Chrome of Firefox.